{"id":4938,"date":"2022-04-05T02:04:21","date_gmt":"2022-04-05T02:04:21","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=4938"},"modified":"2023-08-29T17:53:37","modified_gmt":"2023-08-29T17:53:37","slug":"prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=4938","title":{"rendered":"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c"},"content":{"rendered":"

Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002<\/p>\n

\u4eca\u5929\u4e0a\u5348\uff0c\u8be5\u516c\u53f8\u5ba3\u5e03\u5df2\u5f00\u59cb\u62db\u52dfT\u7ec6\u80de\u6dcb\u5df4\u7624\uff08T-cell lymphomas\uff09\u6cbb\u75971b\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u6269\u5c55\u961f\u5217\u4eba\u5458\u3002<\/p>\n

\u5728\u6269\u5c55\u961f\u5217\u4e2d\uff0c8\u81f312\u540d\u590d\u53d1\u96be\u6cbb\u6027T\u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u5c06\u88ab\u7eb3\u5165\u3002<\/p>\n

\u8fd9\u9879\u7814\u7a76\u5c06\u662f\u5f00\u653e\u6807\u7b7e\u3001\u975e\u968f\u673a\u7684\uff0c\u7531\u58a8\u5c14\u672c\u7231\u666e\u6c83\u65af\u533b\u9662\u7684\u4e16\u754c\u8457\u540d\u8840\u6db2\u5b66\u5bb6H Miles Prince\u6559\u6388\u9886\u5bfc\u3002<\/p>\n

Prescient\u6307\u51fa\uff0c1b\u671f\u7814\u7a76\u7684\u201c\u4f18\u79c0\u7684\u5b89\u5168\u6027\u6570\u636e\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u8bc1\u636e\u201d\u5bfc\u81f4\u4e86\u961f\u5217\u7684\u6269\u5927\uff0c\u8be5\u961f\u5217\u5c06\u4e13\u6ce8\u4e8e\u5916\u5468T\u7ec6\u80de\u6dcb\u5df4\u7624(PTCL)\u60a3\u8005\u3002<\/p>\n

\u76ae\u80a4T\u7ec6\u80de\u6dcb\u5df4\u7624(CTCL)\u60a3\u8005\u5c06\u88ab\u7eb3\u5165\u8bd5\u9a8c\uff0c\u4ee5\u63d0\u9ad8\u5bf9\u4efb\u4f55T\u7ec6\u80de\u6dcb\u5df4\u7624\u836f\u7269\u6d3b\u6027\u7684\u8ba4\u8bc6\u3002<\/p>\n

\u4e00\u6279PTX-100\u5df2\u7ecf\u62b5\u8fbe\u6fb3\u5927\u5229\u4e9a\u652f\u6301\u8fd9\u9879\u8bd5\u9a8c\u3002<\/p>\n

\u5148\u77e5\u8ba1\u5212\u5728\u4eca\u5e74\u5e74\u5e95\u5b8c\u6210\u6269\u5145\u961f\u5217\u7684\u62db\u52df\u5de5\u4f5c\u3002<\/p>\n

PTCL\u8840\u6db2\u764c\u75c7<\/h2>\n

PTCL\u6307\u7684\u662f\u4e00\u7ec4\u4e0d\u5e38\u89c1\u7684\u548c\u4fb5\u88ad\u6027\u7684\u764c\u75c7\uff0c\u901a\u5e38\u5f71\u54cd60\u5c81\u53ca\u4ee5\u4e0a\u7684\u4eba\u3002<\/p>\n

\u5f53\u75c5\u4eba\u7684T\u7ec6\u80de(\u514d\u75ab\u7cfb\u7edf\u7684\u91cd\u8981\u7ec4\u6210\u90e8\u5206)\u751f\u957f\u8fc7\u5feb\u800c\u5931\u53bb\u63a7\u5236\u65f6\uff0c\u5c31\u4f1a\u53d1\u751f\u764c\u53d8\u3002<\/p>\n

\u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u5305\u62ec\u8054\u5408\u5316\u7597\u65b9\u6848\u3001\u653e\u7597\u3001\u5e72\u7ec6\u80de\u79fb\u690d\u548c\u7c7b\u56fa\u9187\u6cbb\u7597\u3002<\/p>\n

\u201c\u9f13\u52b1\u521d\u6b65\u8bc1\u636e\u201d<\/h2>\n

\u5728\u6700\u521d\u76841b\u671f\u7814\u7a76\u4e2d\uff0c\u4e00\u540dPTCL\u60a3\u8005\u7ecf\u5386\u4e8637\u4e2a\u6cbb\u7597\u5468\u671f\uff0c\u5e76\u4f7f\u7528PTX-100\u3002<\/p>\n

Prescient\u8bf4\uff0c\u8fd9\u540d\u60a3\u8005\u60a3\u6709\u201c\u7279\u522b\u4e25\u91cd\u7684\u75be\u75c5\u201d\uff0c\u4e4b\u524d\u76845\u79cd\u6cbb\u7597\u65b9\u6cd5\u90fd\u5931\u8d25\u4e86\uff0c\u5728\u75c5\u60c5\u6076\u5316\u524d\u7684\u51e0\u4e2a\u6708\u91cc\u90fd\u65e0\u6cd5\u63a7\u5236\u75c5\u60c5\u3002<\/p>\n

\u8be5\u516c\u53f8\u8868\u793a:\u201c\u5f53\u4f7f\u7528PTX-100\u6cbb\u7597\u65f6\uff0c\u8fd9\u540d\u60a3\u8005\u7ecf\u5386\u4e86\u90e8\u5206\u7f13\u89e3(\u764c\u75c7\u8d1f\u62c5\u51cf\u8f7b)\uff0c\u8fd9\u79cd\u7f13\u89e3\u8fc4\u4eca\u5df2\u6301\u7eed\u4e8624\u4e2a\u6708\u3002\u201d<\/p>\n

\u53e6\u4e00\u540dCTCL\u60a3\u8005\u4e4b\u524d\u4e09\u6b21\u6cbb\u7597\u5931\u8d25\uff0c\u4e5f\u6709\u4fb5\u88ad\u6027\u75be\u75c5\u3002<\/p>\n

\u5f53\u4f7f\u7528PTX-100\u6cbb\u7597\u65f6\uff0c\u8be5\u60a3\u8005\u4e5f\u6709\u90e8\u5206\u53cd\u5e94\uff0c\u764c\u635f\u51cf\u5c11\uff0c\u75c7\u72b6\u7f13\u89e3\u3002<\/p>\n

\u8be5\u60a3\u8005\u63a5\u53d7PTX-100\u6cbb\u759712\u4e2a\u6708\u3002<\/p>\n

\u672a\u6ee1\u8db3\u7684\u9700\u6c42<\/h2>\n

\u636ePrescient\u79f0\uff0c\u8fd9\u79cd\u75be\u75c5\u60a3\u8005\u7684\u6807\u51c6\u6cbb\u7597\u9884\u8ba1\u4f1a\u57284\u4e2a\u6708\u5185\u51fa\u73b0\u75be\u75c5\u8fdb\u5c55\u3002<\/p>\n

\u6709\u5148\u89c1\u4e4b\u660e\u7684\u9996\u5e2d\u6267\u884c\u5b98\u548c\u5e38\u52a1\u8463\u4e8bSteven Yatomi-Clarke\u8bf4\uff0c\u76ee\u524d\u5bf9PTCL\u8840\u764c\u7f3a\u4e4f\u6709\u6548\u7684\u6cbb\u7597\u9009\u62e9\u3002<\/p>\n

\u4ed6\u8bf4\uff0c\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u6cbb\u7597\u9700\u6c42\u53ef\u80fd\u4f1a\u4e3aPTX-100\u63d0\u4f9b\u66f4\u77ed\u7684\u76d1\u7ba1\u8def\u5f84\u548c\u6700\u5feb\u7684\u4e0a\u5e02\u9014\u5f84\u3002<\/p>\n

\u201c\u6839\u636e\u5728\u8fd9\u4e2a\u6269\u5c55\u961f\u5217\u4e2d\u89c2\u5bdf\u5230\u7684\u6709\u6548\u6027\uff0c\u53ef\u80fd\u4f1a\u8fdb\u884c\u4e00\u4e2a\u540e\u7eed\u7684\u6ce8\u518c\u7814\u7a76\uff0c\u6bd4\u901a\u5e38\u5728\u5176\u4ed6\u764c\u75c7\u8bd5\u9a8c\u4e2d\u770b\u5230\u7684\u5927\u578bIII\u671f\u7814\u7a76\u66f4\u5c0f\u3001\u66f4\u77ed\u3002\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002 \u4eca\u5929\u4e0a\u5348\uff0c\u8be5\u516c\u53f8\u5ba3\u5e03\u5df2\u5f00\u59cb\u62db\u52dfT\u7ec6\u80de\u6dcb\u5df4\u7624\uff08T-cell lymphomas\uff09\u6cbb\u75971b\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u6269\u5c55\u961f\u5217\u4eba\u5458\u3002 \u5728\u6269\u5c55\u961f\u5217\u4e2d\uff0c8\u81f312\u540d\u590d\u53d1\u96be\u6cbb\u6027T\u7ec6\u80de\u6dcb\u5df4\u7624\u60a3\u8005\u5c06\u88ab\u7eb3\u5165\u3002 \u8fd9\u9879\u7814\u7a76\u5c06\u662f\u5f00\u653e\u6807\u7b7e\u3001\u975e\u968f\u673a\u7684\uff0c\u7531\u58a8\u5c14\u672c\u7231\u666e\u6c83\u65af\u533b\u9662\u7684\u4e16\u754c\u8457\u540d\u8840\u6db2\u5b66\u5bb6H Miles Prince\u6559\u6388\u9886\u5bfc\u3002 Prescient\u6307\u51fa\uff0c1b\u671f\u7814\u7a76\u7684\u201c\u4f18\u79c0\u7684\u5b89\u5168\u6027\u6570\u636e\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u521d\u6b65\u8bc1\u636e\u201d\u5bfc\u81f4\u4e86\u961f\u5217\u7684\u6269\u5927\uff0c\u8be5\u961f\u5217\u5c06\u4e13\u6ce8\u4e8e\u5916\u5468T\u7ec6\u80de\u6dcb\u5df4\u7624(PTCL)\u60a3\u8005\u3002 \u76ae\u80a4T\u7ec6\u80de\u6dcb\u5df4\u7624(CTCL)\u60a3\u8005\u5c06\u88ab\u7eb3\u5165\u8bd5\u9a8c\uff0c\u4ee5\u63d0\u9ad8\u5bf9\u4efb\u4f55T\u7ec6\u80de\u6dcb\u5df4\u7624\u836f\u7269\u6d3b\u6027\u7684\u8ba4\u8bc6\u3002 \u4e00\u6279PTX-100\u5df2\u7ecf\u62b5\u8fbe\u6fb3\u5927\u5229\u4e9a\u652f\u6301\u8fd9\u9879\u8bd5\u9a8c\u3002 \u5148\u77e5\u8ba1\u5212\u5728\u4eca\u5e74\u5e74\u5e95\u5b8c\u6210\u6269\u5145\u961f\u5217\u7684\u62db\u52df\u5de5\u4f5c\u3002 PTCL\u8840\u6db2\u764c\u75c7 PTCL\u6307\u7684\u662f\u4e00\u7ec4\u4e0d\u5e38\u89c1\u7684\u548c\u4fb5\u88ad\u6027\u7684\u764c\u75c7\uff0c\u901a\u5e38\u5f71\u54cd60\u5c81\u53ca\u4ee5\u4e0a\u7684\u4eba\u3002 \u5f53\u75c5\u4eba\u7684T\u7ec6\u80de(\u514d\u75ab\u7cfb\u7edf\u7684\u91cd\u8981\u7ec4\u6210\u90e8\u5206)\u751f\u957f\u8fc7\u5feb\u800c\u5931\u53bb\u63a7\u5236\u65f6\uff0c\u5c31\u4f1a\u53d1\u751f\u764c\u53d8\u3002 \u76ee\u524d\u7684\u6cbb\u7597\u65b9\u6cd5\u5305\u62ec\u8054\u5408\u5316\u7597\u65b9\u6848\u3001\u653e\u7597\u3001\u5e72\u7ec6\u80de\u79fb\u690d\u548c\u7c7b\u56fa\u9187\u6cbb\u7597\u3002 \u201c\u9f13\u52b1\u521d\u6b65\u8bc1\u636e\u201d \u5728\u6700\u521d\u76841b\u671f\u7814\u7a76\u4e2d\uff0c\u4e00\u540dPTCL\u60a3\u8005\u7ecf\u5386\u4e8637\u4e2a\u6cbb\u7597\u5468\u671f\uff0c\u5e76\u4f7f\u7528PTX-100\u3002 Prescient\u8bf4\uff0c\u8fd9\u540d\u60a3\u8005\u60a3\u6709\u201c\u7279\u522b\u4e25\u91cd\u7684\u75be\u75c5\u201d\uff0c\u4e4b\u524d\u76845\u79cd\u6cbb\u7597\u65b9\u6cd5\u90fd\u5931\u8d25\u4e86\uff0c\u5728\u75c5\u60c5\u6076\u5316\u524d\u7684\u51e0\u4e2a\u6708\u91cc\u90fd\u65e0\u6cd5\u63a7\u5236\u75c5\u60c5\u3002 \u8be5\u516c\u53f8\u8868\u793a:\u201c\u5f53\u4f7f\u7528PTX-100\u6cbb\u7597\u65f6\uff0c\u8fd9\u540d\u60a3\u8005\u7ecf\u5386\u4e86\u90e8\u5206\u7f13\u89e3(\u764c\u75c7\u8d1f\u62c5\u51cf\u8f7b)\uff0c\u8fd9\u79cd\u7f13\u89e3\u8fc4\u4eca\u5df2\u6301\u7eed\u4e8624\u4e2a\u6708\u3002\u201d \u53e6\u4e00\u540dCTCL\u60a3\u8005\u4e4b\u524d\u4e09\u6b21\u6cbb\u7597\u5931\u8d25\uff0c\u4e5f\u6709\u4fb5\u88ad\u6027\u75be\u75c5\u3002 \u5f53\u4f7f\u7528PTX-100\u6cbb\u7597\u65f6\uff0c\u8be5\u60a3\u8005\u4e5f\u6709\u90e8\u5206\u53cd\u5e94\uff0c\u764c\u635f\u51cf\u5c11\uff0c\u75c7\u72b6\u7f13\u89e3\u3002 \u8be5\u60a3\u8005\u63a5\u53d7PTX-100\u6cbb\u759712\u4e2a\u6708\u3002 \u672a\u6ee1\u8db3\u7684\u9700\u6c42 \u636ePrescient\u79f0\uff0c\u8fd9\u79cd\u75be\u75c5\u60a3\u8005\u7684\u6807\u51c6\u6cbb\u7597\u9884\u8ba1\u4f1a\u57284\u4e2a\u6708\u5185\u51fa\u73b0\u75be\u75c5\u8fdb\u5c55\u3002 \u6709\u5148\u89c1\u4e4b\u660e\u7684\u9996\u5e2d\u6267\u884c\u5b98\u548c\u5e38\u52a1\u8463\u4e8bSteven Yatomi-Clarke\u8bf4\uff0c\u76ee\u524d\u5bf9PTCL\u8840\u764c\u7f3a\u4e4f\u6709\u6548\u7684\u6cbb\u7597\u9009\u62e9\u3002 \u4ed6\u8bf4\uff0c\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u6cbb\u7597\u9700\u6c42\u53ef\u80fd\u4f1a\u4e3aPTX-100\u63d0\u4f9b\u66f4\u77ed\u7684\u76d1\u7ba1\u8def\u5f84\u548c\u6700\u5feb\u7684\u4e0a\u5e02\u9014\u5f84\u3002 \u201c\u6839\u636e\u5728\u8fd9\u4e2a\u6269\u5c55\u961f\u5217\u4e2d\u89c2\u5bdf\u5230\u7684\u6709\u6548\u6027\uff0c\u53ef\u80fd\u4f1a\u8fdb\u884c\u4e00\u4e2a\u540e\u7eed\u7684\u6ce8\u518c\u7814\u7a76\uff0c\u6bd4\u901a\u5e38\u5728\u5176\u4ed6\u764c\u75c7\u8bd5\u9a8c\u4e2d\u770b\u5230\u7684\u5927\u578bIII\u671f\u7814\u7a76\u66f4\u5c0f\u3001\u66f4\u77ed\u3002\u201d<\/p>\n","protected":false},"author":3,"featured_media":18318,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[171],"yoast_head":"\nPrescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-05T02:04:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:53:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Prescient-Therapeutics-ASX-PTX-PTX-100-T-Cell-Lymphoma-white-blood-cell-cancer-study-phase-1B.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/\",\"name\":\"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-04-05T02:04:21+00:00\",\"dateModified\":\"2023-08-29T17:53:37+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c","description":"Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c","og_description":"Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/","og_site_name":"smallcapsCN","article_published_time":"2022-04-05T02:04:21+00:00","article_modified_time":"2023-08-29T17:53:37+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Prescient-Therapeutics-ASX-PTX-PTX-100-T-Cell-Lymphoma-white-blood-cell-cancer-study-phase-1B.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/","url":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/","name":"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-04-05T02:04:21+00:00","dateModified":"2023-08-29T17:53:37+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"Prescient Therapeutics (ASX: PTX)\u5df2\u7ecf\u5f00\u59cb\u62db\u52df\u4e00\u9879\u6269\u5927\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269PTX-100\u6cbb\u7597\u4fb5\u7565\u6027\u7f55\u89c1\u8840\u764c\uff0c\u8be5\u516c\u53f8\u8868\u793a\u6709\u201c\u663e\u8457\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u5f97\u5230\u6ee1\u8db3\u201d\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-begins-recruiting-expanded-trial-ptx-100-blood-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics\u5f00\u59cb\u62db\u52df\u7528\u4e8e\u8840\u764c\u7684PTX-100\u6269\u5927\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4938"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4938"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4938\/revisions"}],"predecessor-version":[{"id":14817,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4938\/revisions\/14817"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18318"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}